Status:
UNKNOWN
CXCL10 As a Biomarker Of ILD in Patients WithRA
Lead Sponsor:
Assiut University
Conditions:
Interstitial Lung Disease in Patients With Rheumatoid Arthritis
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Rheumatoid arthritis is a chronic inflammatory disease that affects the joints, causing symmetric pain, stiffness, swelling, and limited motion and function of multiple joints, its fibro inflammatory man...
Detailed Description
Rheumatoid arthritis is complicated by lung manifestations, such as interstitial lung disease which is the most common cause of morbidity and mortality in rheumatoid arthritis patients. Rheumatoid art...
Eligibility Criteria
Inclusion
- Adult rheumatoid arthritis patients who fulfilled the 2010 American College of Rheumatology/European league against rheumatism criteria for the classification of Rheumatoid Arthritis.
- Adult rheumatoid arthritis patients with interstitial lung disease.
Exclusion
- Individuals with other autoimmune diseases (systemic lupus erythematosus, polyarteritis nodosa, dermatomyositis, scleroderma, spondyloarthritis and inflammatory bowel disease).
- Individuals with hepatitis, Rhinovirus infection, cerebral malaria.
- Individuals with colorectal carcinoma, syndrome of frailty, vetiligo.
Key Trial Info
Start Date :
December 19 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 19 2022
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04356066
Start Date
December 19 2020
End Date
January 19 2022
Last Update
April 22 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.